Guidelines on the Diagnosis, Clinical Assessments, Treatment and Management for CLN2 Disease Patients

Рекомендации по диагностике, клинической оценке, лечению и ведению пациентов с заболеванием CLN2
Ingrid Eileen Scheffer, Jonathan W. Mink, Nicola Specchio, Paul Gissen, Raymond Wang, Samuel Frank Berkovic, Sara Mole, Maurizio Scarpa, Angela Schulz, Alessandro Simonati, Emily de los Reyes, Ëben Badoe, Simon Dulz, Noreen Murphy, Miriam Nickel, Joffre E. Olaya, Ina von Löbbecke, Ruth Elizabeth Williams, Norberto Gilbert, Charles Marquez Lourenço
2020-10-28

CLN2 diseaselysosomal storage diseasemodified Delphi consensusneuronal ceroid lipofuscinosis type 2tripeptidyl peptidase 1
Abstract Background: CLN2 disease (Neuronal Ceroid Lipofuscinosis Type 2), or Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL), is an ultra-rare, neurodegenerative lysosomal storage disease, caused by an enzyme deficiency of tripeptidyl peptidase 1 (TPP1). Lack of disease awareness and the non-specificity of presenting symptoms often leads to delayed diagnosis. These guidelines provide robust evidence-based, expert-agreed recommendations on the risks/benefits of disease-modifying treatments and the medical interventions used to manage this condition. Methods: An expert mapping tool process was developed ranking multidisciplinary professionals, with knowledge of CLN2 disease, diagnostic or management experience of CLN2 disease, or family support professionals. Individuals were sequentially approached to identify two chairs, ensuring that the process was transparent and unbiased. A systematic literature review of published evidence using PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidance was independently and simultaneously conducted to develop key statements based upon the strength of the publications. Clinical care statements formed the basis of an international modified Delphi consensus determination process using the virtual meeting (Within3) online platform which requested experts to agree or disagree with any changes. Statements reaching the consensus mark became the guiding statements within this manuscript, which were subsequently assessed against the Appraisal of Guidelines for Research and Evaluation (AGREEII) criteria.Results: Twenty-one international experts from 7 different specialities, including a patient advocate, were identified. Fifty-three guideline statements were developed covering 13 domains: General Description and Statements, Diagnostics, Clinical Recommendations and Management, Assessments, Interventions and Treatment, Additional Care Considerations, Social Care Considerations, Pain Management, Epilepsy / Seizures, Nutritional Care Interventions, Respiratory Health, Sleep and Rest, and End of Life Care. Consensus was reached after a single round of voting, with one exception which was revised, and agreed by 100% of the SC and achieved 80% consensus in the second voting round. The overall AGREE II assessment score obtained for the development of the guidelines was 5.7 (where 1 represents the lowest quality, and 7 represents the highest quality). Conclusion: This program provides robust evidence- and consensus-driven guidelines that can be used by all healthcare professionals involved in the management of patients with CLN2 disease. This addresses the clinical need to complement other information available.
1
An international panel of 21 experts from seven specialties, including a patient advocate, contributed to the guideline-development process.
2
Systematic literature review and a modified Delphi consensus process produced 53 statements across 13 clinical and care domains.
3
The guidelines address disease-modifying treatment risks and benefits, diagnostic evaluation, clinical management, assessments, interventions, and supportive care.
4
The guidelines aim to reduce delayed diagnosis caused by limited disease awareness and nonspecific presenting symptoms in CLN2 disease.
5
The paper develops evidence-based, expert-consensus guidelines for diagnosing, assessing, treating, and managing CLN2 disease.

CLN2 disease (late-infantile neuronal ceroid lipofuscinosis), including its clinical diagnosis and management context

Evidence-based diagnosis, clinical assessment, disease-modifying treatment, and comprehensive medical management of CLN2 disease

Publication Details
Publication Date
2020-10-28
Journal
Publisher
ISSN
Cited by
4
Access Type
Author Information
Authors
Ingrid Eileen Scheffer
Jonathan W. Mink
Nicola Specchio
Paul Gissen
Raymond Wang
Samuel Frank Berkovic
Sara Mole
Maurizio Scarpa
Angela Schulz
Alessandro Simonati
Emily de los Reyes
Ëben Badoe
Simon Dulz
Noreen Murphy
Miriam Nickel
Joffre E. Olaya
Ina von Löbbecke
Ruth Elizabeth Williams
Norberto Gilbert
Charles Marquez Lourenço
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%